South Korea Aminoglycoside Market Size, Share, and COVID-19 Impact Analysis, By Product (Neomycin, Tobramycin, Gentamicin, Amikacin, Paromomycin, Streptomycin, Kanamycin, and Others), By Route of Administration (Injectables (Parenteral), Intra-mammary, Topical, Oral, and Others), By Application (Veterinary, Skin Infection, Respiratory Diseases, UTI and Pelvic Diseases, and Others), and South Korea Aminoglycoside Market Insights, Industry Trend, Forecasts to 2035

South Korea Aminoglycoside Market Insights Forecasts to 2035

• The South Korea Aminoglycoside Market Size Was Estimated at USD 32.2 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.54% from 2025 to 2035
• The South Korea Aminoglycoside Market Size is Expected to Reach USD 58.3 Million by 2035

According to a research report published by Spherical Insights & Consulting, the South Korea Aminoglycoside Market is anticipated to reach USD 58.3 million by 2035, growing at a CAGR of 5.54% from 2025 to 2035. The South Korea aminoglycoside market will grow as the method of administering aminoglycosides varies based on the infection's type and location, along with whether the treatment is intended for a human or non-human patient.

Market Overview

The aminoglycoside market is an integral component of the pharmaceutical industry, driven by the need for effective drugs against gram-negative bacterial infections. Aminoglycosides contain gentamicin and amikacin, which are vital in the treatment of diseases such as sepsis and respiratory infections. The market's growth is driven by the increasing prevalence of chronic diseases and the rising demand for affordable generic medicines. Market opportunities involve enhancements in drug delivery systems and ongoing research into counteracting aminoglycoside resistance. The purpose of these innovations is to improve the safety and efficacy profiles of existing treatments. Market opportunities involve enhancements in drug delivery systems and ongoing research into overcoming aminoglycoside resistance. These innovations are intended to enhance the efficacy and safety profiles of current treatments. The government's commitment to promoting biopharmaceutical capabilities is reflected through considerable research and development expenditures, including the establishment of the Osong Life Science Complex and the National Bio Committee. These initiatives may enhance the aminoglycoside market and provide the public with effective and affordable treatments.

Report Coverage

This research report categorizes the market for the South Korea aminoglycoside market based on various segments and regions forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the South Korea aminoglycoside market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the South Korea aminoglycoside market.

Driving Factors

The increase in bacterial infections, especially within healthcare environments, is crucial in driving the growth of the aminoglycosides market. These antibiotics are effective against a broad spectrum of bacteria, which has led to their extensive use in treating infections. The rising occurrence of surgical procedures in South Korea has resulted in a heightened demand for aminoglycosides to prevent post-surgical infections. Healthcare facilities prioritize infection prevention and control measures, this trend is enhancing the market. Aminoglycosides have become increasingly important due to their effectiveness against drug-resistant bacterial strains. The need for efficient antibiotics to combat drug-resistant infections is a key factor propelling the market.

Restraining Factors

Aminoglycosides are associated with the risk of ototoxicity and nephrotoxicity, which restricts their use among specific groups of patients. Healthcare providers look for safer alternatives, and worries about negative consequences significantly restrict the market. There are competing alternatives in the market such as antibiotics that operate through various mechanisms and have less toxicity. The existence of these alternatives affects the use of aminoglycosides, especially in situations where other antibiotics are shown to be equally or more effective.

Market Segmentation

The South Korea aminoglycoside market share is classified into product, route of administration, and application.

• The gentamicin segment dominated the market in 2023 and is projected to grow at a substantial CAGR during the forecast period.

Based on the product, the South Korea aminoglycoside market is divided into neomycin, tobramycin, gentamicin, amikacin, paromomycin, streptomycin, kanamycin, and others. Among these, the gentamicin segment dominated the market in 2023 and is projected to grow at a substantial CAGR during the forecast period. The segmental growth is due to gentamicin, a strong aminoglycoside antibiotic employed in the treatment of bacterial infections. A variety of gentamicin products are offered by Xellia Pharmaceuticals, comprising injectable solutions that are utilized in hospitals.

• The injectables (parenteral) segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period.

Based on the route of administration, the South Korea aminoglycoside market is divided into injectables (parenteral), intra-mammary, topical, oral, and others. Among these, the injectables (parenteral) segment accounted for a significant share in 2023 and is anticipated to grow at a remarkable CAGR during the forecast period. The segmental growth is due to the segment is expanding due to the increasing necessity of creating safer and more effective treatment options for patients.

• The respiratory diseases segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the South Korea aminoglycoside market is divided into veterinary, skin infection, respiratory diseases, UTI and pelvic diseases, and others. Among these, the respiratory diseases segment accounted for the largest share in 2023 and is anticipated to grow at a significant CAGR during the forecast period. The growth is driven by the increasing necessity of combating respiratory diseases is accelerating the market.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the South Korea aminoglycoside market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Pfizer Inc.
• AbbVie Inc. (Allergan Plc)
• Teva Pharmaceutical Industries Ltd.
• Cipla Limited
• Zoetis Inc.
• Kremoint Pharma Pvt. Ltd.
• Vega Pharma Ltd.
• Jiangxi Bolai Pharmacy Co. Ltd.
• Xian Wison Biological Technology Co. Ltd.
• Hangzhou Uniwise International Co. Ltd.
• Others

Recent Developments:

• In November 2023, the major development for the pharmaceutical sector, Pfizer made a substantial acquisition of Nektar Therapeutics for $7.5 billion. This tactical acquisition enhances Pfizer's antibiotic offerings, with a particular emphasis on the aminoglycosides sector. NKT-477, Nektar’s leading candidate, is in Phase 3 trials to fight multidrug-resistant Pseudomonas aeruginosa infections. This acquisition is set to expedite the development and marketing of NKT-477, which could serve as a vital weapon in the fight against the growing menace of superbugs.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at South Korea, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the South Korea aminoglycoside market based on the below-mentioned segments:

South Korea Aminoglycoside Market, By Product

• Neomycin
• Tobramycin
• Gentamicin
• Amikacin
• Paromomycin
• Streptomycin
• Kanamycin
• Others

South Korea Aminoglycoside Market, By Route of Administration

•  Injectables (Parenteral)
•  Intra-mammary
•  Topical
•  Oral
•  Others

South Korea Aminoglycoside Market, By Application

• Veterinary
• Skin Infection
• Respiratory Diseases
• UTI and Pelvic Diseases
• Others